Found 22 Enz. Inhib. hit(s) with all data for entry = 6642 TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Gruenenthal
US Patent
Gruenenthal
US Patent
Affinity DataKi: 3nMAssay Description:The FLIPR protocol consists of 2 substance additions. First the compounds to be tested (10 uM) are pipetted onto the cells and the Ca2+ influx is com...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Gruenenthal
US Patent
Gruenenthal
US Patent
Affinity DataKi: 3nMAssay Description:The FLIPR protocol consists of 2 substance additions. First the compounds to be tested (10 uM) are pipetted onto the cells and the Ca2+ influx is com...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Gruenenthal
US Patent
Gruenenthal
US Patent
Affinity DataKi: 4nMAssay Description:The FLIPR protocol consists of 2 substance additions. First the compounds to be tested (10 uM) are pipetted onto the cells and the Ca2+ influx is com...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Gruenenthal
US Patent
Gruenenthal
US Patent
Affinity DataKi: 4nMAssay Description:The FLIPR protocol consists of 2 substance additions. First the compounds to be tested (10 uM) are pipetted onto the cells and the Ca2+ influx is com...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Gruenenthal
US Patent
Gruenenthal
US Patent
Affinity DataKi: 5nMAssay Description:The FLIPR protocol consists of 2 substance additions. First the compounds to be tested (10 uM) are pipetted onto the cells and the Ca2+ influx is com...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Gruenenthal
US Patent
Gruenenthal
US Patent
Affinity DataKi: 6nMAssay Description:The FLIPR protocol consists of 2 substance additions. First the compounds to be tested (10 uM) are pipetted onto the cells and the Ca2+ influx is com...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Gruenenthal
US Patent
Gruenenthal
US Patent
Affinity DataKi: 6nMAssay Description:The FLIPR protocol consists of 2 substance additions. First the compounds to be tested (10 uM) are pipetted onto the cells and the Ca2+ influx is com...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Gruenenthal
US Patent
Gruenenthal
US Patent
Affinity DataKi: 7nMAssay Description:The FLIPR protocol consists of 2 substance additions. First the compounds to be tested (10 uM) are pipetted onto the cells and the Ca2+ influx is com...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Gruenenthal
US Patent
Gruenenthal
US Patent
Affinity DataKi: 7nMAssay Description:The FLIPR protocol consists of 2 substance additions. First the compounds to be tested (10 uM) are pipetted onto the cells and the Ca2+ influx is com...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Gruenenthal
US Patent
Gruenenthal
US Patent
Affinity DataKi: 9nMAssay Description:The FLIPR protocol consists of 2 substance additions. First the compounds to be tested (10 uM) are pipetted onto the cells and the Ca2+ influx is com...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Gruenenthal
US Patent
Gruenenthal
US Patent
Affinity DataKi: 10nMAssay Description:The FLIPR protocol consists of 2 substance additions. First the compounds to be tested (10 uM) are pipetted onto the cells and the Ca2+ influx is com...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Gruenenthal
US Patent
Gruenenthal
US Patent
Affinity DataKi: 10nMAssay Description:The FLIPR protocol consists of 2 substance additions. First the compounds to be tested (10 uM) are pipetted onto the cells and the Ca2+ influx is com...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Gruenenthal
US Patent
Gruenenthal
US Patent
Affinity DataKi: 15nMAssay Description:The FLIPR protocol consists of 2 substance additions. First the compounds to be tested (10 uM) are pipetted onto the cells and the Ca2+ influx is com...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Gruenenthal
US Patent
Gruenenthal
US Patent
Affinity DataKi: 23nMAssay Description:The FLIPR protocol consists of 2 substance additions. First the compounds to be tested (10 uM) are pipetted onto the cells and the Ca2+ influx is com...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Gruenenthal
US Patent
Gruenenthal
US Patent
Affinity DataKi: 23nMAssay Description:The FLIPR protocol consists of 2 substance additions. First the compounds to be tested (10 uM) are pipetted onto the cells and the Ca2+ influx is com...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Gruenenthal
US Patent
Gruenenthal
US Patent
Affinity DataKi: 24nMAssay Description:The FLIPR protocol consists of 2 substance additions. First the compounds to be tested (10 uM) are pipetted onto the cells and the Ca2+ influx is com...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Gruenenthal
US Patent
Gruenenthal
US Patent
Affinity DataKi: 31nMAssay Description:The FLIPR protocol consists of 2 substance additions. First the compounds to be tested (10 uM) are pipetted onto the cells and the Ca2+ influx is com...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Gruenenthal
US Patent
Gruenenthal
US Patent
Affinity DataKi: 37nMAssay Description:The FLIPR protocol consists of 2 substance additions. First the compounds to be tested (10 uM) are pipetted onto the cells and the Ca2+ influx is com...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Gruenenthal
US Patent
Gruenenthal
US Patent
Affinity DataKi: 45nMAssay Description:The FLIPR protocol consists of 2 substance additions. First the compounds to be tested (10 uM) are pipetted onto the cells and the Ca2+ influx is com...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Gruenenthal
US Patent
Gruenenthal
US Patent
Affinity DataKi: 66nMAssay Description:The FLIPR protocol consists of 2 substance additions. First the compounds to be tested (10 uM) are pipetted onto the cells and the Ca2+ influx is com...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Gruenenthal
US Patent
Gruenenthal
US Patent
Affinity DataKi: 73nMAssay Description:The FLIPR protocol consists of 2 substance additions. First the compounds to be tested (10 uM) are pipetted onto the cells and the Ca2+ influx is com...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Gruenenthal
US Patent
Gruenenthal
US Patent
Affinity DataKi: 74nMAssay Description:The FLIPR protocol consists of 2 substance additions. First the compounds to be tested (10 uM) are pipetted onto the cells and the Ca2+ influx is com...More data for this Ligand-Target Pair
